Glycodelin Expression in Pancreatic Neuroendocrine and Solid-Pseudopapillary Tumors as in Important Factor of Favorable Disease Prognosis Abstract #240

Introduction: Glycodelin (GD) is a multifunctional highly glycosylated protein, expressed in hormone-dependent human tissues and tumors. GD participates in apoptosis regulation and inter-cellular adhesion.
Aim(s): To assess GD production and progesterone receptors' (PR) role in pancreatic malignant tumor cells.
Materials and methods: Forty-three pancreatic tumor specimens examined: 19 neuroendocrine tumors (NET), 14 solid-pseudopapillary (SPT), 10 exocrine carcinomas. We used a semiquantitative method (1-3+) to evaluate cytoplasmic type of GD expression in tumor cells; to evaluate PR expression used PR-index (%) and H score similar to one used in breast cancers.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Larissa Gurevich

To read results and conclusion, please login ...

Further abstracts you may be interested in

#232 Prognostic Factors and Survival in 481 Patients with Pancreatic and Peripancreatic Endocrine Tumors: Results from the National Cancer Registry of Spain (RGETNE)
Introduction: Duodenopancreatic neuroendocrine tumors (NETs) are uncommon neoplasms with a wide spectrum of clinical presentation. The infrequent occurrence of these tumors makes large experiences very scarce.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Elena Martin-Perez
#239 CK 19 Expression in Pancreatic Neuroendocrine Tumors as Negative Prognostic Factor and a Risk Factor for Metastases
Introduction: Neuroendocrine tumors (NET) of the pancreas are slow growing neoplasms, but they can metastasize after many years after surgery.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Larisa Gurevich
#1282 Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Frequency, Treatment and Prognosis
Introduction: Data on peritoneal metastases (PM) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are scarce.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Ariana Madani
#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations
Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr Anguraj Sadanandam
#74 Non-functioning pancreatic endocrine tumors: diagnostic criteria and surgical treatment
Introduction: Neuroendocrine tumors were considered rare tumors several years ago. Several reports published recently have observed increased incidence of NETs suggesting that NETs are more prevalent than previously reported. Non-functioning pancreatic endocrine tumors (NFPETs), better defined as non-hyperfunctioning, are characterized by the absence of clinical or biochemical evidence of hormone hypersecretion. From the clinical standpoint, NFPETs can be either occasionally encountered or manifest clinically similar pancreatic tumors. Since both NFPET treatment and prognosis significantly differ from that of ductal adenocarcinoma and other pancreatic malignant tumors, an accurate differential diagnosis is needed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Alexander Vladimir Kochatkov